Headlines about Beigene (NASDAQ:BGNE) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Beigene earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5293202732081 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern’s rankings:
- Beigene (BGNE) Given Overweight Rating at Morgan Stanley (americanbankingnews.com)
- Beigene Ltd (BGNE) CFO Howard Liang Sells 10,872 Shares (americanbankingnews.com)
- Beigene Ltd (BGNE) CFO Howard Liang Sells 40,000 Shares (americanbankingnews.com)
- Today’s Research Reports on Trending Tickers: BeiGene and Exact Sciences (finance.yahoo.com)
- Beigene Ltd (BGNE) Expected to Post Quarterly Sales of $16.27 Million (americanbankingnews.com)
BGNE has been the topic of a number of recent research reports. Cowen reiterated a “buy” rating on shares of Beigene in a report on Monday, December 11th. BidaskClub lowered shares of Beigene from a “buy” rating to a “hold” rating in a report on Saturday, January 13th. Zacks Investment Research downgraded shares of Beigene from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $172.00 target price on shares of Beigene in a research note on Thursday, March 1st. They noted that the move was a valuation call. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $138.00 price target on shares of Beigene in a research note on Thursday, March 1st. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $145.17.
Beigene (NASDAQ:BGNE) last released its earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The business had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $23.00 million. equities analysts predict that Beigene will post -7.69 EPS for the current fiscal year.
In other news, CFO Howard Liang sold 10,872 shares of the stock in a transaction on Friday, March 16th. The shares were sold at an average price of $157.07, for a total value of $1,707,665.04. Following the transaction, the chief financial officer now owns 15,872 shares of the company’s stock, valued at approximately $2,493,015.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the firm’s stock in a transaction dated Thursday, January 18th. The stock was bought at an average cost of $101.00 per share, for a total transaction of $199,999,998.00. The disclosure for this purchase can be found here. Insiders have sold a total of 214,347 shares of company stock worth $30,984,091 over the last 90 days. 19.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Beigene (NASDAQ:BGNE) Earning Somewhat Favorable News Coverage, Study Shows” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/22/beigene-bgne-receives-coverage-optimism-rating-of-0-20/1927322.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.